S&P 500   3,283.85 (+0.23%)
DOW   28,859.39 (+0.48%)
QQQ   221.76 (+0.14%)
AAPL   325.18 (+2.36%)
FB   221.06 (+1.50%)
MSFT   167.02 (+0.94%)
GOOGL   1,450.63 (+0.01%)
AMZN   1,861.87 (+0.47%)
CGC   23.97 (+0.21%)
MU   56.16 (-0.55%)
GE   12.98 (+10.66%)
TSLA   572.80 (+1.04%)
AMD   46.91 (-7.16%)
T   37.57 (-2.62%)
ACB   1.99 (+1.02%)
NFLX   345.33 (-0.92%)
BAC   33.38 (+0.39%)
GILD   64.45 (+0.14%)
S&P 500   3,283.85 (+0.23%)
DOW   28,859.39 (+0.48%)
QQQ   221.76 (+0.14%)
AAPL   325.18 (+2.36%)
FB   221.06 (+1.50%)
MSFT   167.02 (+0.94%)
GOOGL   1,450.63 (+0.01%)
AMZN   1,861.87 (+0.47%)
CGC   23.97 (+0.21%)
MU   56.16 (-0.55%)
GE   12.98 (+10.66%)
TSLA   572.80 (+1.04%)
AMD   46.91 (-7.16%)
T   37.57 (-2.62%)
ACB   1.99 (+1.02%)
NFLX   345.33 (-0.92%)
BAC   33.38 (+0.39%)
GILD   64.45 (+0.14%)
S&P 500   3,283.85 (+0.23%)
DOW   28,859.39 (+0.48%)
QQQ   221.76 (+0.14%)
AAPL   325.18 (+2.36%)
FB   221.06 (+1.50%)
MSFT   167.02 (+0.94%)
GOOGL   1,450.63 (+0.01%)
AMZN   1,861.87 (+0.47%)
CGC   23.97 (+0.21%)
MU   56.16 (-0.55%)
GE   12.98 (+10.66%)
TSLA   572.80 (+1.04%)
AMD   46.91 (-7.16%)
T   37.57 (-2.62%)
ACB   1.99 (+1.02%)
NFLX   345.33 (-0.92%)
BAC   33.38 (+0.39%)
GILD   64.45 (+0.14%)
S&P 500   3,283.85 (+0.23%)
DOW   28,859.39 (+0.48%)
QQQ   221.76 (+0.14%)
AAPL   325.18 (+2.36%)
FB   221.06 (+1.50%)
MSFT   167.02 (+0.94%)
GOOGL   1,450.63 (+0.01%)
AMZN   1,861.87 (+0.47%)
CGC   23.97 (+0.21%)
MU   56.16 (-0.55%)
GE   12.98 (+10.66%)
TSLA   572.80 (+1.04%)
AMD   46.91 (-7.16%)
T   37.57 (-2.62%)
ACB   1.99 (+1.02%)
NFLX   345.33 (-0.92%)
BAC   33.38 (+0.39%)
GILD   64.45 (+0.14%)
Log in

NASDAQ:MNLO - Menlo Therapeutics Stock Price, Forecast & News

$5.39
-0.03 (-0.55 %)
(As of 01/29/2020 10:50 AM ET)
Today's Range
$5.39
Now: $5.39
$5.67
50-Day Range
$4.07
MA: $5.24
$6.93
52-Week Range
$2.69
Now: $5.39
$9.03
Volume8,447 shs
Average Volume239,637 shs
Market Capitalization$131.52 million
P/E RatioN/A
Dividend YieldN/A
Beta2.09
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNLO
CUSIPN/A
Phone650-486-1416

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.64 million
Book Value$5.61 per share

Profitability

Net Income$-51,440,000.00

Miscellaneous

Employees43
Market Cap$131.52 million
Next Earnings Date2/26/2020 (Estimated)
OptionableNot Optionable

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.


Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc (NASDAQ:MNLO) posted its quarterly earnings data on Thursday, October, 31st. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.77) by $0.07. View Menlo Therapeutics' Earnings History.

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Menlo Therapeutics.

What price target have analysts set for MNLO?

2 brokerages have issued 1 year price targets for Menlo Therapeutics' shares. Their forecasts range from $11.00 to $25.00. On average, they expect Menlo Therapeutics' stock price to reach $18.00 in the next year. This suggests a possible upside of 230.9% from the stock's current price. View Analyst Price Targets for Menlo Therapeutics.

What is the consensus analysts' recommendation for Menlo Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Menlo Therapeutics.

Has Menlo Therapeutics been receiving favorable news coverage?

Media stories about MNLO stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Menlo Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Menlo Therapeutics.

Are investors shorting Menlo Therapeutics?

Menlo Therapeutics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 311,900 shares, an increase of 112.6% from the December 31st total of 146,700 shares. Based on an average daily volume of 123,000 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.7% of the shares of the company are short sold. View Menlo Therapeutics' Current Options Chain.

Who are some of Menlo Therapeutics' key competitors?

What other stocks do shareholders of Menlo Therapeutics own?

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the folowing people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 53)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 47)
  • Dr. Mary C. Spellman, Chief Medical Officer (Age 57)
  • Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 48)
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an IPO on Thursday, January 25th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and JMP Securities was co-manager.

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $5.44.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $132.74 million and generates $10.64 million in revenue each year. The company earns $-51,440,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis. Menlo Therapeutics employs 43 workers across the globe.View Additional Information About Menlo Therapeutics.

What is Menlo Therapeutics' official website?

The official website for Menlo Therapeutics is http://www.menlotherapeutics.com/.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected]


MarketBeat Community Rating for Menlo Therapeutics (NASDAQ MNLO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Featured Article: What is Depreciation?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel